Additional file 1: of Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
Teresa Kauf
Vimalanand Prabhu
Goran Medic
Rebekah Borse
Benjamin Miller
Jennifer Gaultney
Shuvayu Sen
Anirban Basu
10.6084/m9.figshare.c.3767567_D1.v1
https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Cost-effectiveness_of_ceftolozane_tazobactam_compared_with_piperacillin_tazobactam_as_empiric_therapy_based_on_the_in-vitro_surveillance_of_bacterial_isolates_in_the_United_States_for_the_treatment_of_complicated_urinary_tract_infecti/4954739
Details regarding PACTS and Premier data. This additional file provides readers with additional details regarding the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS) dataset which was used to provide susceptibility inputs for the model and also regarding the Premier research database which was used to help define the pathogen distribution in cUTI. (DOCX 29 kb)
2017-04-28 05:00:00
Cost-benefit analysis
Ceftolozane
Piperacillin
Tazobactam
Urinary tract infections
United States
Drug resistance